Processes for preparing substituted...

Details Processes for preparing substituted... Processes for preparing substituted...

2004-07-21

2010-10-12

Saeed, Kamal A (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07812176

ABSTRACT:
The present invention is directed to processes for the preparation of substituted phenylpyrazole ureas of Formula (I), that are useful as 5-HT2Aserotonin receptor modulators for the treatment of disease.

REFERENCES:
patent: 4099012 (1978-07-01), Gschwend
patent: 4405644 (1983-09-01), Kabbe et al.
patent: 4409231 (1983-10-01), Stenzel et al.
patent: 4985352 (1991-01-01), Julius et al.
patent: 5077409 (1991-12-01), Wissner
patent: 5128351 (1992-07-01), Wissner
patent: 5523280 (1996-06-01), Chene et al.
patent: 5661024 (1997-08-01), Kao et al.
patent: 5885785 (1999-03-01), Kao et al.
patent: 5886044 (1999-03-01), Widdowson et al.
patent: 5905080 (1999-05-01), Duckworth et al.
patent: 5945382 (1999-08-01), Cantegril et al.
patent: 5990133 (1999-11-01), Gaster et al.
patent: 6005008 (1999-12-01), Widdowson et al.
patent: 6028085 (2000-02-01), Bromidge
patent: 6054472 (2000-04-01), Armistead et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6271261 (2001-08-01), Widdowson
patent: 6297261 (2001-10-01), Christophersen et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6383762 (2002-05-01), Kao et al.
patent: 6417393 (2002-07-01), Christophersen et al.
patent: 6420541 (2002-07-01), Behan et al.
patent: 6479480 (2002-11-01), Moyes et al.
patent: 6479519 (2002-11-01), Astles et al.
patent: 6531291 (2003-03-01), Kabbash et al.
patent: 6541209 (2003-04-01), Behan et al.
patent: 6696475 (2004-02-01), Dahl et al.
patent: 6706749 (2004-03-01), Dahl et al.
patent: 6784183 (2004-08-01), Lavielle et al.
patent: 6846919 (2005-01-01), Behan et al.
patent: 7368539 (2008-05-01), Behan et al.
patent: 2002/0025965 (2002-02-01), Lavielle et al.
patent: 2002/0098548 (2002-07-01), Kao et al.
patent: 2004/0102636 (2004-05-01), Miller et al.
patent: 2005/0054691 (2005-03-01), Potter et al.
patent: 2005/0080124 (2005-04-01), Teegarden et al.
patent: 2005/0267097 (2005-12-01), Pinto et al.
patent: 2006/0014705 (2006-01-01), Howitz et al.
patent: 2006/0063754 (2006-03-01), Edgar et al.
patent: 2006/0205792 (2006-09-01), Wong et al.
patent: 2006/0229335 (2006-10-01), Teegarden et al.
patent: 2007/0037827 (2007-02-01), Nunes et al.
patent: 2007/0072857 (2007-03-01), Teegarden et al.
patent: 2007/0207994 (2007-09-01), Teegarden et al.
patent: 2007/0244086 (2007-10-01), Teegarden et al.
patent: 2007/0293685 (2007-12-01), Fritch et al.
patent: 2008/0015223 (2008-01-01), Strah-Pleynet et al.
patent: 2008/0200530 (2008-08-01), Unett et al.
patent: 2009/0053306 (2009-02-01), Agarwal et al.
patent: 2009/0076254 (2009-03-01), Behan et al.
patent: 2009/0186895 (2009-07-01), Teegarden et al.
patent: 2009/0197935 (2009-08-01), Teegarden et al.
patent: 2135253 (1996-05-01), None
patent: 1108720 (2001-06-01), None
patent: 1 558 582 (2005-08-01), None
patent: 1734039 (2006-12-01), None
patent: 2 722 369 (1996-01-01), None
patent: 1147379 (1967-12-01), None
patent: WO 96/02138 (1996-02-01), None
patent: WO 96/10559 (1996-04-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 97/03967 (1997-02-01), None
patent: WO 97/45111 (1997-12-01), None
patent: WO 98/24785 (1998-06-01), None
patent: WO 99/06354 (1999-02-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 99/32927 (1999-07-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 00/64866 (2000-11-01), None
patent: WO 01/21160 (2001-03-01), None
patent: WO 01/29008 (2001-04-01), None
patent: WO 02/39987 (2002-05-01), None
patent: WO 02/051833 (2002-07-01), None
patent: WO 02/076464 (2002-10-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2004-01-01), None
patent: WO 2004/028450 (2004-04-01), None
patent: WO 2004/045118 (2004-05-01), None
patent: WO 2004/058722 (2004-07-01), None
patent: WO 2004/071426 (2004-08-01), None
patent: WO 2004/028450 (2004-10-01), None
patent: WO 2004/085433 (2004-10-01), None
patent: WO 2004/096771 (2004-11-01), None
patent: WO2005012254 (2005-02-01), None
patent: WO 2005/077345 (2005-08-01), None
patent: WO 2005/103011 (2005-11-01), None
patent: WO 2006/018662 (2006-02-01), None
patent: WO 2006/049734 (2006-05-01), None
patent: WO 2006/049941 (2006-05-01), None
patent: WO 2006/055734 (2006-05-01), None
patent: WO 2006/059149 (2006-06-01), None
patent: WO 2006/060654 (2006-06-01), None
patent: WO 2006/070394 (2006-07-01), None
patent: WO 2006/076592 (2006-07-01), None
patent: WO 2006/078610 (2006-07-01), None
patent: WO 2006/079637 (2006-08-01), None
patent: WO2006/081335 (2006-08-01), None
patent: WO 2006/086705 (2006-08-01), None
patent: WO 2006/089871 (2006-08-01), None
patent: WO 2006/095205 (2006-09-01), None
patent: WO 2006/097766 (2006-09-01), None
patent: WO 2006/100519 (2006-09-01), None
patent: WO 2006/112464 (2006-10-01), None
patent: WO 2006/116614 (2006-11-01), None
patent: WO 2007/002559 (2007-01-01), None
patent: WO 2007/026959 (2007-03-01), None
patent: WO 2007/120600 (2007-10-01), None
patent: WO 2007/129111 (2007-11-01), None
patent: WO 2007/136680 (2007-11-01), None
patent: WO 2007/136703 (2007-11-01), None
patent: WO 2007/136875 (2007-11-01), None
patent: WO 2008/027483 (2008-03-01), None
patent: WO 2008/042388 (2008-04-01), None
patent: WO 2008/054748 (2008-05-01), None
patent: WO 2009/023253 (2009-02-01), None
Andrzejewska-Buczko et al., “Serotonin in diabetic retinopathyl”, Klin Oczna Feb. 1996; 98(2):101-4 (abstract only).
Berge et al., “Pharmaceutical salts”, J. of Pharmaceutical Sciences (1977) 66(1):1-19.
Cameron et al., “The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats”, Naunyn Schmiedebergs Arch Pharmacol, Jun. 2003; 367(6):607-14.
Casey et al., “Constitutively active mutant 5HT2Aserotonin receptors: inverse agonist activity of classical 5HT2Aantagonists”, Society for Neuroscience Abstracts, vol. 22, p. 699.10.
Cazzola et al., “5-HT modifiers as a potential treatment of asthma”, TIPS, 2000, vol. 21, p. 13.
Chang et al., “Mechanism of the ocular hypotensive action of ketanserin”, J Ocul Pharmacol., 1985 Summer; 1(2):137-47.
Cohen-Mansfield et al., “Agitated behaviors in the elderly. I. A conceptual review”, J. Am. Geriatr. Soc., Oct. 1986; 34(10):711-21.
Collier et al., “Radiosynthesis and in-vivo evaluation of the pseudopeptide δ-opioid antagonist [125]-ITIPP(ψ)”, J. Labeled Compd. Radiopharm., 1999, vol. 42, pp. S264-S266.
Collins et al., “N-Phenylamidines as Selective Inhibitors of Human Neuronal Nitric Oxide Synthase: Structure-Activity Studies and Demonstration of in Vivi Activity”,Journal of Medicinal Chemistry, American Chemical Society, 41, No. 15, pp. 2858-2871, 1998; XP0022144154.
De Bie et al., “Modulation of airway hyperresponsiveness and eosinophilia by selective histamine and 5-HT receptor antagonists in a mouse model of allergic asthma”, British Journal of Pharmacology, 1998, vol. 124:857-864.
Greene et al., Protecting Groups in Organic Synthesis, 3rdEdition, 1999 (Wiley).
Grunder et al., Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography, Neuropsychopharmacology, Sep. 1997; 17(3):175-85.
Herrick-Davis et al., “Activating mutations of the serotonin 5-HT2C receptor”, J. Neurochem., Sep. 1997; 69(3):1138-44.
Herrick-Davis et al., “Constitutively active 5HT2C serotonin receptor created by site-directed mutagenesis”, Society for Neuroscience Abstracts, vol. 22, p. 699.18.
Higuchi et al., “Pro-drugs and Novel Delivery Systems”, vol. 14 of the ACS Symposium Series; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Katz et al., “Comparison of risperidone and placebo for psychosis and behavioral disturbances associa

Affiliated with

Also associated with

Rating

Processes for preparing substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Processes for preparing substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for preparing substituted... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4152645